NEW YORK (GenomeWeb) – Biodesix said today that its has received a positive coverage decision from Aetna for its VeriStrat test for guiding therapy in patients with non-small cell lung cancer (NSCLC).

According to Biodesix, Aetna has deemed VeriStrat, which uses MALDI mass spec-based proteomic signatures to identify patients likely to respond to treatment with EGFR inhibitors, medically necessary for patients with advanced NSCLC whose tumors were without EGFR and anaplastic lymphoma kinase mutations.

Aetna has approximately 46 million members in the US.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.